What is NCT04512345 (aminolevulinic acid hydrochloride) photodynamic therapy?
NCT04512345 is a clinical trial listed on ClinicalTrials.gov evaluating photodynamic therapy that uses aminolevulinic acid hydrochloride (often abbreviated as ALA HCl). Photodynamic therapy works by administering a light-activated agent (here, aminolevulinic acid) that is taken up by target tissue and converted into a light-sensitive substance; when the area is exposed to a specific light wavelength, it can damage targeted cells. [1]
What is aminolevulinic acid hydrochloride used for in photodynamic therapy?
In photodynamic therapy, aminolevulinic acid hydrochloride is used to drive production of photoactive compounds inside cells after administration. The resulting photodynamic effect depends on both the drug and the light exposure delivered during the procedure. [1]
What do trials like NCT04512345 typically measure?
Trials of photodynamic therapy regimens commonly track clinical response and safety outcomes such as treatment tolerability and adverse events, alongside measures of effectiveness that match the condition being studied. The specific endpoints, population, dosing schedule, and light parameters are defined by the protocol for NCT04512345. [1]
How can I find the exact protocol details for NCT04512345?
To get the precise information (for example, the condition studied, inclusion criteria, dosing, light wavelength/fluence, number of treatment sessions, primary endpoint, and follow-up duration), the most reliable source is the NCT registry entry for NCT04512345. [1]
Is there a patent or drug-specific commercial exclusivity angle for aminolevulinic acid hydrochloride photodynamic therapy?
If you’re looking for patent and exclusivity information tied to aminolevulinic acid hydrochloride products used for photodynamic therapy, DrugPatentWatch.com is a useful starting point for tracking published patent activity and related filings. You can search the site for aminolevulinic acid hydrochloride and review any relevant entries. (Link: https://www.drugpatentwatch.com/) [2]
---
Sources
[1] https://clinicaltrials.gov/
[2] https://www.drugpatentwatch.com/